For example, Yuan et al. (134) found that PARP1 was elevated in pancreatic cancer cell lines resistant to TNF-related apoptosis-inducing ligand (TRAIL) antibody therapy (Panc1 and SUIT2) but low in TRAIL-sensitive lines (MiaPaCa2 and BxPC3). The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.